Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study
Supportive Care in Cancer · 2024
DOI: 10.1007/s00520-024-08604-1 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Amanda Landers und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago, 2 Riccarton Ave, Christchurch Central, Christchurch, 8011, New Zealand. amanda.landers@otago.ac.nz. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Enzyme Replacement Therapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Canterbury Medical Research Foundation, University of Otago.
Abstract (Originalsprache)
Purpose
This study investigated pancreatic enzyme replacement therapy (PERT) use in people diagnosed with pancreatic cancer in New Zealand (NZ) and Australia (AU).
Methods
A cross-sectional survey study was conducted using a mixed-media campaign to recruit people with pancreatic cancer and collect information about current PERT use. The questionnaire gathered data on participant demographics, awareness of PERT, prescribing practices and efficacy of enzyme replacement.
Results
Over 300 people with pancreatic cancer were recruited, 135 from New Zealand and 199 from Australia. Every region, state and territory was represented except for the West Coast (NZ) and the Northern Territory (AU), the lowest populated areas in both countries. In New Zealand, 60% of participants had heard about PERT, compared to 69.3% in Australia. Dosing regimens were inconsistent in both countries, with 18% and 27% of participants being prescribed PERT considered best practice in New Zealand and Australia, respectively. Before PERT commencement, 70% of participants experienced symptoms of malabsorption, with all symptoms improving after therapy was established. The majority of participants were compliant with their medication.
Conclusion
PERT use in pancreatic cancer in New Zealand and Australia was highly variable and not compliant with international guidelines in which PERT is recommended as standard therapy. Enzyme replacement is effective for improving the symptoms of malabsorption in patients with pancreatic cancer. Clinician education may be needed to help improve the use of PERT in people with pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Otago, 2 Riccarton Ave, Christchurch Central, Christchurch, 8011, New Zealand. amanda.landers@otago.ac.nz.
- Nurse Maude Hospice Palliative Care Service, Nurse Maude Association, Christchurch, New Zealand.
- Te Whatu Ora, Wellington, New Zealand.
- Nutrition and Dietetics, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.
- IMPACCT Centre, Faculty of Health, University of Technology Sydney, Sydney, Australia.
- Surgical and Translational Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
ORCID-Profile: Amanda Landers, Vanessa M Yenson
Förderung
- Health Research Council of New Zealand
- Canterbury Medical Research Foundation
- University of Otago
Zitieren
APA
Landers, A., Brown, H., Al Ruheili, J., Russell, K., McKenzie, C., Agar, M. R., Yenson, V. M., Clarke, K., & Windsor, J. (2024). Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08604-1
Vancouver
Landers A, Brown H, Al Ruheili J, Russell K, McKenzie C, Agar MR, et al. Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08604-1
BibTeX
@article{Landers2024,
author = {Landers, Amanda and Brown, Helen and Al Ruheili, Juhaina and Russell, Kylie and McKenzie, Clare and Agar, Meera R and Yenson, Vanessa M and Clarke, Kate and Windsor, John},
title = {Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study},
journal = {Supportive Care in Cancer},
year = {2024},
doi = {10.1007/s00520-024-08604-1}
}
EUVIMED